Barclays Issues Positive Forecast for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN) had its target price increased by Barclays from $7.50 to $8.00 in a report published on Tuesday,Benzinga reports. Barclays currently has an underweight rating on the stock.

A number of other research analysts have also recently weighed in on OGN. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a report on Monday, October 27th. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen cut Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. JPMorgan Chase & Co. cut their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Finally, Morgan Stanley reduced their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and an average price target of $8.50.

Organon & Co. Trading Up 3.1%

NYSE OGN opened at $8.17 on Tuesday. The company has a market cap of $2.12 billion, a P/E ratio of 11.50, a P/E/G ratio of 0.72 and a beta of 0.58. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $16.18. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. The company has a 50-day moving average of $7.97 and a 200-day moving average of $8.50.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 123.06%. Organon & Co.’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.90 earnings per share. As a group, equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd will be paid a dividend of $0.02 per share. The ex-dividend date is Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.0%. Organon & Co.’s dividend payout ratio (DPR) is currently 11.27%.

Institutional Investors Weigh In On Organon & Co.

A number of large investors have recently added to or reduced their stakes in OGN. Royal Bank of Canada lifted its holdings in Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after buying an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after acquiring an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Organon & Co. by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after acquiring an additional 26,640 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Organon & Co. by 33.2% in the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after acquiring an additional 13,925 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in Organon & Co. by 64,378.6% in the second quarter. AlphaQuest LLC now owns 18,054 shares of the company’s stock valued at $175,000 after purchasing an additional 18,026 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.